Cephadol

Cephadol

Manufacturer:

Kenyaku

Distributor:

Schumit
Full Prescribing Info
Contents
Diphenidol hydrochloride.
Description
Cephadol is an antivertigo agent developed from the evaluation on the basis of recent progress of vertigo investigation.
Common name: Diphenidol hydrochloride.
Chemical name: 1, 1-diphenyl-4 piperidino-1-butanol hydrochloride.
Cephadol Tablet contains 25mg of diphenidol hydrochloride.
These years the number of patients complaining about vertigo has increased on account of stresses due to complicated living, environment as well as head and neck injuries by traffic accidents and its sequelae. Thus vertigo is now really one of the typical diseases of the modern age.
Cephadol is an antivertigo agent developed from the evaluation on the basis of recent progress of vertigo investigation.
Action
Characteristics: Improvement of circulation in vertebral basilar arteries: Cephadol releases contraction of vertebral basilar arteries shown in the symptom of vertigo to improve the blood stream and keeps the balance of vertebral artery blood stream on both sides.
As it works selectively against contraction of blood vessel, it would not cause so-called intracerebral steal syndrome and gives almost no effect on the total blood pressure.
Blocking effect against vestibular abnormal stimulation: Cephadol blocks abnormal stimulation at the levels of vestibular nucleus and of hypothalamus.
The previously mentioned blocking actions are specific, almost not influence the upper central nervous system, being by far different from antihistaminics and sedatives.
Clinical effect: From the result of double blind trial, it has been proved that Cephadol is effective for curing vertigo and meniere's disease. As shown in the following tables, episode or vertigo and sensation of dizziness are significantly improved by Cephadol treatment.
As to occurrence of side effect, there is no significant difference between Cephadol and placebo-treated groups. (See Tables 1 and 2.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

It has been confirmed by analyzing the result of double blind trial by cross-over method that the physical abnormalities being found by tilt and caloric tests are significantly improved by Cephadol treatment.
Righting reflex and unbalance of right and left eye speeds due to nystagmus are normalized to arrive at equilibrium state.
Also in balance function examinations (stepping test, righting reflex test, nystagmographic studies, writing test, blood rheography by Doppler's method).
Cephadol brought improvement as well as it showed to subjective symptoms, thus being highly evaluated as a purposeful antivertigo agent.
With the improvements of vertigo, fainting sensation and the balance function examinations, the associated complaints such as tinnitus and deafness in meniere's disease and labyrinthitis, heavy-headedness, headache and stiff shoulder in head and whiplash injuries, and palpitation and shortness of breath in circulatory disturbance are also removed.
From the clinical results obtained, it can be said that Cephadol is effective in 75% of the previously mentioned symptoms.
As to the side effect, transient appearance of thirst, heartburn, mydriasis, palpitation, etc., are reported in small cases, but the number differs little from the one observed in the administration of placebo, and these side effects are disappeared by reducing or pausing the administration.
No abnormality is seen in liver and kidney function tests after the treatment.
Indications/Uses
Vertigo caused by inner ear disturbance.
Dosage/Direction for Use
Usually for adult, 1-2 tablets, 3 times daily.
The dose is increased or decreased by age and symptoms. Administration after meals is preferable.
Special Precautions
Do not apply to the patients who are sensitive to drugs or who have serious disturbances on renal functions.
Reduce or pause when thirst, heartburn, mydriasis, palpitation, etc., are observed by the administration of this drug. In addition to the previous text pay attention to occurrences of rash, discomfort feeling, heavy feeling in head, drowsiness.
MIMS Class
ATC Classification
N07CA - Antivertigo preparations ; Used in the treatment of vertigo.
Presentation/Packing
Tab 25 mg x 20 x 10's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in